Tá dul chun cinn mór i bhforbairt drugaí meall inchinn óige. Is galar urchóideach níos coitianta i leanaí iad tumaí inchinn leanaí. Fuair taighde le déanaí amach gur féidir le druga mhanglaim nua siadaí inchinn coitianta óige a chóireáil.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain siadaí each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common siadaí urchóideacha of the cerebellum. This meall inchinne grows rapidly and most often occurs in children around the age of 5. Roghanna cóireála include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed ailse cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Trí chomhcheangal le drugaí eile, déantar comhdhúile nua a choisceann siadaí a scagadh in vitro agus in vivo.
Trialacha cliniciúla for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
“Más féidir linn cóireálacha saincheaptha a fhorbairt bunaithe ar ghéinte meall - straitéis dá ngairtear cóireáil aonair go coitianta - d’fhéadfadh sé seo soiscéal ollmhór a thabhairt d’othair a bhfuil siadaí áirithe orthu."
Tá ceithre chineál ar leith de neuroblastoma ann, agus tá an prognóis is measa ag othair le tríú grúpa siadaí - ní mhaireann ach 40% d’othair go fadtéarmach. I gcodarsnacht leis sin, tá maireachtáil fhadtéarmach neuroblastomas eile réasúnta dóchasach, agus is féidir le thart ar 80% d’othair maireachtáil go fadtéarmach.
Tá ard-léiriú ag an gcuid is mó den tríú grúpa othar le neuroblastoma ar an oncogene MYC, agus is é sin is cúis le deighilt neamhrialaithe cille agus foirmiú siadaí.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s I i Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other cineálacha ailse, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block cill ailse maireachtáil.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
